Payment overview · 2025
General Payments
$1,088.14
62 reported records · 13 companies
Healthcare provider profile · identity verified
Gregory Anthony George, M.D.
Allopathic & Osteopathic Physicians|Family Medicine|Adult Medicine · SHARON, PA · NPI 1417909243
Verified facts
What the public records show
CMS Open Payments records show Gregory Anthony George, M.D. received $1,088.14 in general payments during 2025 across 62 reported records.
GlaxoSmithKline, LLC. accounted for 23.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Linzess, Mounjaro, Ozempic, Rexulti, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 368 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 368 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $249.82 | 23.0% | 13 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $184.55 | 17.0% | 16 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $161.44 | 14.8% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $158.85 | 14.6% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $68.29 | 6.3% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $66.54 | 6.1% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $64.12 | 5.9% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $36.59 | 3.4% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $22.48 | 2.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.63 | 2.0% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $19.94 | 1.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.37 | 1.6% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $16.52 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,088.14 | 62 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $249.82 | 13 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $184.55 | 16 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $161.44 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $139.85 | 7 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $137.50 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $104.78 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $64.12 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $51.86 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $41.57 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $36.59 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $36.59 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $32.42 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $22.48 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.92 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $17.37 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $16.52 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $16.43 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.20 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 368 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 63 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 51 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 134 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
61 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
63 | 18 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
368 | 62 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
134 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
85 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
51 | 12 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
368 | 62 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 642 | 146 |
| Pantoprazole Sodium | Pantoprazole Sodium | 614 | 169 |
| Amlodipine Besylate | Amlodipine Besylate | 601 | 140 |
| Atorvastatin Calcium | Atorvastatin Calcium | 553 | 128 |
| Gabapentin | Gabapentin | 469 | 106 |
| Lisinopril | Lisinopril | 448 | 127 |
| Metformin Hcl | Metformin Hcl | 432 | 97 |
| Metoprolol Tartrate | Metoprolol Tartrate | 387 | 82 |
| Eliquis | Apixaban | 368 | 62 |
| Tramadol Hcl | Tramadol Hcl | 368 | 81 |
| Potassium Chloride | Potassium Chloride | 335 | 83 |
| Omeprazole | Omeprazole | 303 | 74 |
| Losartan Potassium | Losartan Potassium | 288 | 80 |
| Furosemide | Furosemide | 271 | 88 |
| Pravastatin Sodium | Pravastatin Sodium | 260 | 54 |
| Duloxetine Hcl | Duloxetine Hcl | 257 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 254 | 68 |
| Metoprolol Succinate | Metoprolol Succinate | 233 | 72 |
| Carvedilol | Carvedilol | 218 | 45 |
| Clopidogrel | Clopidogrel Bisulfate | 211 | 48 |
| Azithromycin | Azithromycin | 200 | 145 |
| Methylprednisolone | Methylprednisolone | 195 | 138 |
| Trazodone Hcl | Trazodone Hcl | 194 | 50 |
| Levetiracetam | Levetiracetam | 193 | 27 |
| Alprazolam | Alprazolam | 182 | 23 |
| Sertraline Hcl | Sertraline Hcl | 181 | 38 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 171 | 31 |
| Lorazepam | Lorazepam | 170 | 43 |
| Xarelto | Rivaroxaban | 167 | 34 |
| Oxycodone Hcl | Oxycodone Hcl | 165 | 36 |
| Sucralfate | Sucralfate | 157 | 35 |
| Azelastine Hcl | Azelastine Hcl | 155 | 95 |
| Hydrochlorothiazide | Hydrochlorothiazide | 153 | 54 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 150 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 141 | 44 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 137 | 49 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 135 | 39 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 134 | 37 |
| Mirtazapine | Mirtazapine | 132 | 22 |
| Amoxicillin | Amoxicillin | 130 | 99 |
| Escitalopram Oxalate | Escitalopram Oxalate | 128 | 22 |
| Donepezil Hcl | Donepezil Hcl | 124 | 20 |
| Ondansetron Hcl | Ondansetron Hcl | 122 | 42 |
| Naproxen | Naproxen | 121 | 51 |
| Finasteride | Finasteride | 118 | 23 |
| Simvastatin | Simvastatin | 105 | 29 |
| Quetiapine Fumarate | Quetiapine Fumarate | 104 | 22 |
| Atenolol | Atenolol | 103 | 25 |
| Warfarin Sodium | Warfarin Sodium | 100 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 96 | 68 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 95 | 16 |
| Allopurinol | Allopurinol | 94 | 20 |
| Famotidine | Famotidine | 89 | 20 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 88 | 51 |
| Jardiance | Empagliflozin | 85 | 24 |
| Glipizide | Glipizide | 82 | 19 |
| Meclizine Hcl | Meclizine Hcl | 82 | 36 |
| Spironolactone | Spironolactone | 79 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 78 | 26 |
| Lamotrigine | Lamotrigine | 76 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 75 | 22 |
| Prednisone | Prednisone | 70 | 21 |
| Ibuprofen | Ibuprofen | 69 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 68 | 12 |
| Divalproex Sodium | Divalproex Sodium | 67 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 67 | 18 |
| Memantine Hcl | Memantine Hcl | 65 | 12 |
| Farxiga | Dapagliflozin Propanediol | 63 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 63 | 19 |
| Clonazepam | Clonazepam | 61 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 61 | 11 |
| Synthroid | Levothyroxine Sodium | 61 | 18 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 60 | 18 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 60 | 20 |
| Amiodarone Hcl | Amiodarone Hcl | 59 | 13 |
| Humalog Kwikpen U-100 | Insulin Lispro | 58 | 12 |
| Trulicity | Dulaglutide | 58 | suppressed |
| Entresto | Sacubitril/Valsartan | 57 | 11 |
| Risperidone | Risperidone | 57 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 56 | 15 |
| Glipizide Er | Glipizide | 55 | 13 |
| Cephalexin | Cephalexin | 54 | 43 |
| Lactulose | Lactulose | 54 | 21 |
| Aripiprazole | Aripiprazole | 53 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 53 | 14 |
| Digoxin | Digoxin | 53 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 53 | 14 |
| Pregabalin | Pregabalin | 53 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 52 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 51 | suppressed |
| Ozempic | Semaglutide | 51 | 12 |
| Meloxicam | Meloxicam | 50 | 13 |
| Bumetanide | Bumetanide | 49 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 48 | 12 |
| Buspirone Hcl | Buspirone Hcl | 47 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 45 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 45 | 27 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 45 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 45 | 17 |
| Olanzapine | Olanzapine | 45 | suppressed |
| Baclofen | Baclofen | 41 | suppressed |
| Fentanyl | Fentanyl | 41 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 40 | 22 |
| Bupropion Xl | Bupropion Hcl | 39 | 15 |
| Celecoxib | Celecoxib | 39 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 39 | 12 |
| Tradjenta | Linagliptin | 39 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 37 | 28 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Constulose | Lactulose | 37 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 37 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 36 | 27 |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Mounjaro | Tirzepatide | 34 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 34 | suppressed |
| Diazepam | Diazepam | 33 | suppressed |
| Topiramate | Topiramate | 33 | suppressed |
| Zonisamide | Zonisamide | 33 | suppressed |
| Ezetimibe | Ezetimibe | 32 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 31 | 15 |
| Latanoprost | Latanoprost | 31 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 31 | suppressed |
| Anastrozole | Anastrozole | 30 | suppressed |
| Linzess | Linaclotide | 30 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 30 | 15 |
| Ranolazine Er | Ranolazine | 30 | suppressed |
| Valsartan | Valsartan | 30 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 29 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 28 | 13 |
| Haloperidol | Haloperidol | 28 | suppressed |
| Hydrocortisone | Hydrocortisone | 27 | 11 |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | suppressed |
| Lidocaine | Lidocaine | 26 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 26 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 24 | 12 |
| Irbesartan | Irbesartan | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Repaglinide | Repaglinide | 24 | suppressed |
| Vascepa | Icosapent Ethyl | 24 | suppressed |
| Novolog | Insulin Aspart | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 23 | suppressed |
| Nystatin | Nystatin | 22 | 13 |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Modafinil | Modafinil | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 17 |
| Mupirocin | Mupirocin | 20 | 13 |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Ertapenem | Ertapenem Sodium | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 19 | suppressed |
| Torsemide | Torsemide | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Cholestyramine Light | Cholestyramine | 18 | suppressed |
| Daptomycin | Daptomycin | 18 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 15 |
| Midodrine Hcl | Midodrine Hcl | 18 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 18 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 17 | 11 |
| Clindamycin Hcl | Clindamycin Hcl | 17 | 13 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 17 | suppressed |
| Carisoprodol | Carisoprodol | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 16 | 12 |
| Lithium Carbonate | Lithium Carbonate | 16 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Amantadine | Amantadine Hcl | 15 | suppressed |
| Cefadroxil | Cefadroxil | 15 | suppressed |
| Lacosamide | Lacosamide | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Pentasa | Mesalamine | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Epinephrine | Epinephrine | 14 | suppressed |
| Ramelteon | Ramelteon | 14 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Betaxolol Hcl | Betaxolol Hcl | 12 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 12 | suppressed |
| Entacapone | Entacapone | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 12 | suppressed |
| Oxazepam | Oxazepam | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Budesonide Er | Budesonide | 11 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 11 | suppressed |
| Klayesta | Nystatin | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Rexulti | Brexpiprazole | 11 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 11 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,088.14 · 62 records | GlaxoSmithKline, LLC. | AIRSUPRA, AUSTEDO XR, BREZTRI, CAPLYTA, Cologuard Collection Kit, ELIQUIS, FARXIGA, LINZESS, MOUNJARO, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, VRAYLAR, XIFAXAN, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error